English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Objective . Comparing activity of 2 regimens combining oxaliplatin to bolus modulated fluorouracil as second line treatment in advanced pancreatic adenocarcinoma pretreated with gemcitabine-containing schedule.  Methods . Forty eight patients with advanced pancreatic adenocarcinoma were randomly assigned to receive either FU 500 mg/m 2  IV bolus weekly ×6 weeks plus leucovorin 500 mg/m 2  IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85 mg/m 2  IV on weeks 1, 3, and 5 of each 8-week (FLOX) OR receive weekly intravenous infusions of oxaliplatin 40 mg/m 2 , 5-FU 500 mg/m 2 , and leucovorin 250 mg/m 2  (3 weeks on, 1 week off).  Results . Non progression(PR+SD) was found in 33.5% for first regimen and 29% for second regimen, and 37.5% had  clinical benefit  (FLOX regimen) compared to 50% in 3-weeks regimen. The median TTP was 3.9,4 months respectively. Median OS was 8, 9 months for both regimens. Only one case in 3-weeks arm suffered from grade IV diarrhea. Two cases &gt; grade 2 neutropenia were observed; one in each treatment groups. Grade 3 anemia was recorded in 3 patients (2 in FLOX arm, one in 3-weeks arm).  Conclusions . Both regimens showed encouraging efficacy, acceptable toxicity, and clinical benefit.

isrn oncology

Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace FOLFOX When Considered for Second Line?